通过网络药理和分子对接验证银止黄颗粒治疗乙型肝炎的分

StephenW

A Bioinformatics Investigation Into Molecular Mechanism of Yinzhihuang Granules for Treating Hepatitis B by Network Pharmacology and Molecular Docking Verification
Jingyuan Zhang  1 , Xinkui Liu  1 , Wei Zhou  1 , Guoliang Cheng  2 , Jiarui Wu  3 , Siyu Guo  1 , Shanshan Jia  1 , Yingying Liu  1 , Bingbing Li  2 , Xiaomeng Zhang  1 , Miaomiao Wang  1
Affiliations
Affiliations

    1
    Beijing University of Chinese Medicine, Beijing, 100102, China.
    2
    State Key Laboratory of Generic Manufacture Technology of Chinese Traditional Medicine, Linyi, 276000, China.
    3
    Beijing University of Chinese Medicine, Beijing, 100102, China. [email protected].

    PMID: 32651427 DOI: 10.1038/s41598-020-68224-7

Abstract

Yinzhihuang granules (YZHG) is a patented Chinese medicine for the treatment of hepatitis B. This study aimed to investigate the intrinsic mechanisms of YZHG in the treatment of hepatitis B and to provide new evidence and insights for its clinical application. The chemical compounds of YZHG were searched in the CNKI and PUBMED databases, and their putative targets were then predicted through a search of the SuperPred and Swiss Target Prediction databases. In addition, the targets of hepatitis B were obtained from TTD, PharmGKB and DisGeNET. The abovementioned data were visualized using Cytoscape 3.7.1, and network construction identified a total of 13 potential targets of YZHG in the treatment of hepatitis B. Molecular docking verification showed that CDK6, CDK2, TP53 and BRCA1 might be strongly correlated with hepatitis B treatment. Furthermore, GO and KEGG analyses indicated that the treatment of hepatitis B by YZHG might be related to positive regulation of transcription, positive regulation of gene expression, the hepatitis B pathway and the viral carcinogenesis pathway. Network pharmacology intuitively shows the multicomponent, multitarget and multichannel pharmacological effects of YZHG in the treatment of hepatitis B and provides a scientific basis for its mechanism of action.

StephenW

通过网络药理和分子对接验证银止黄颗粒治疗乙型肝炎的分子机制生物信息学研究
张敬源1，刘新奎1，周伟1，成国良2，吴佳瑞3，郭思宇1，贾珊珊1，刘颖颖1，李冰冰2，张晓萌1，王妙苗1
隶属关系
隶属关系

    1个
    北京中医药大学，北京100102
    2
    中药仿制药技术国家重点实验室，临沂276000
    3
    北京中医药大学，北京100102 [email protected]。

    PMID：32651427 DOI：10.1038 / s41598-020-68224-7

抽象

银止黄颗粒（YZHG）是治疗乙肝的专利中药。本研究旨在探讨YZHG在乙肝治疗中的内在机理，为其临床应用提供新的证据和见解。在CNKI和PUBMED数据库中搜索YZHG的化合物，然后通过搜索SuperPred和Swiss Target Prediction数据库预测其推定目标。此外，乙型肝炎的目标是从TTD，PharmGKB和DisGeNET获得的。使用Cytoscape 3.7.1可视化上述数据，网络建设确定了乙肝治疗中YZHG的总共13个潜在靶标。分子对接验证显示CDK6，CDK2，TP53和BRCA1可能与乙肝治疗密切相关。此外，GO和KEGG分析表明，YZHG治疗乙型肝炎可能与转录的正调控，基因表达的正调控，乙型肝炎途径和病毒致癌途径有关。网络药理学直观地显示了YZHG在乙型肝炎治疗中的多成分，多靶点和多通道药理作用，并为其作用机理提供了科学依据。

StephenW

https://www.nature.com/articles/s41598-020-68224-7.pdf

lancas

这。。。。百度也搜不到这个药。。。银止黄颗粒是什么个鬼。。。CNKI和万方数据库也没有任何的资料~~~